Mazdutide vs Tirzepatide: Dual GLP-1/Glucagon Agonism vs GIP/GLP-1 Co-Agonism

Mazdutide vs tirzepatide is one of the most frequently raised comparisons in current incretin research, as both compounds pair GLP-1 receptor agonism with a second metabolic receptor target to drive weight and glycemic outcomes beyond what selective GLP-1 agonists achieve alone. Tirzepatide, a dual GLP-1/GIP receptor agonist, is FDA-approved and has anchored the field's efficacy benchmark since the SURPASS trial program. Mazdutide, a GLP-1/glucagon receptor (GCGR) dual agonist developed by Innovent Biologics in collaboration with Eli Lilly, has completed Phase 3 registration trials and received approval in China, offering researchers a structurally distinct approach to the same clinical problem.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.

Quick Answer: Mazdutide and tirzepatide are both once-weekly dual-receptor incretin agonists, but they pair GLP-1 agonism with different second receptors — mazdutide adds glucagon receptor (GCGR) activation for hepatic and thermogenic effects, while tirzepatide adds GIP receptor (GIPR) activation for enhanced insulin sensitization; tirzepatide is FDA-approved in the US, while mazdutide is approved in China and remains investigational elsewhere.

TL;DR:

• Mazdutide (IBI362) is a GLP-1/glucagon (GCGR) dual agonist; tirzepatide is a GLP-1/GIP (GIPR) dual agonist — different second-receptor targets produce different downstream effects.
• Phase 3 GLORY-1 data (NEJM, 2025) shows mazdutide 6 mg produced 14.01% mean body weight reduction at 48 weeks, with liver fat content reduced by up to 80.2%.
• Tirzepatide's SURPASS program and subsequent real-world cohort data show sustained multi-system benefits, including improved lipid, hepatic, and renal parameters with long-term persistence.
• Tirzepatide holds FDA approval for type 2 diabetes and chronic weight management; mazdutide holds NMPA (China) approval, with Phase 3 DREAMS-3 comparing it head-to-head against semaglutide still ongoing.
• Mazdutide's glucagon-receptor component is associated with pronounced hepatic fat reduction, a differentiator researchers cite when studying metabolic-associated liver disease alongside weight outcomes.

Mazdutide: mechanism and evidence base

Mazdutide (IBI362, also referred to as OXM3) is a 30-amino acid acylated peptide built on a modified oxyntomodulin backbone with a C18 fatty acid chain for half-life extension, dosed once weekly by subcutaneous injection. It activates both the GLP-1 receptor and the glucagon receptor (GCGR) with balanced dual agonism. The GLP-1R component slows gastric emptying, promotes satiety, and enhances glucose-dependent insulin secretion — the same core mechanism shared across the incretin class. The GCGR component is the structural differentiator: glucagon receptor activation drives hepatic fatty acid oxidation, increases energy expenditure through thermogenesis, and produces direct lipolytic effects that are complementary to, rather than redundant with, GLP-1R signaling.

Phase 2 data (NCT04904913) in Chinese adults with overweight or obesity found mean body weight reductions of −6.7%, −10.4%, and −11.3% at 24 weeks for the 3 mg, 4.5 mg, and 6 mg doses respectively, versus +1.0% with placebo (PMID 38092790). Phase 3 GLORY-1 (NCT05607680), published in NEJM in 2025, enrolled 610 participants and reported −11.00% weight reduction at the 4 mg dose and −14.01% at 6 mg over 48 weeks, alongside liver fat content reductions of up to 80.2% — a magnitude of hepatic effect that researchers attribute to the added GCGR agonism. Phase 3 GLORY-2 (NCT06164873) using a 9 mg dose reported weight reductions up to 20.1%. A head-to-head Phase 3 trial, DREAMS-3, comparing mazdutide against semaglutide in participants with type 2 diabetes and obesity, is ongoing. Mazdutide has received approval from China's National Medical Products Administration for both type 2 diabetes and obesity management, making it the first Chinese-developed GLP-1/GCGR dual agonist to complete global Phase 3 registration trials.

Tirzepatide: mechanism and evidence base

Tirzepatide is a 39-amino acid dual GLP-1/GIP receptor agonist, engineered as a single peptide with balanced affinity for both incretin receptors and a fatty diacid moiety enabling albumin binding and once-weekly dosing. Unlike mazdutide's GLP-1/glucagon pairing, tirzepatide combines GLP-1R agonism with glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism. GIPR activation was historically considered a weaker contributor to weight loss on its own, but tirzepatide's SURPASS trial program demonstrated that co-agonism at GIPR produces additive effects on insulin sensitization and adipose tissue metabolism when combined with GLP-1R activation, exceeding what selective GLP-1 agonists achieve.

Beyond the original SURPASS efficacy data, real-world persistence-cohort research (PMID 42029986) evaluating adults with obesity but without type 2 diabetes found that tirzepatide's benefits extend across the cardio-metabolic-kidney continuum and scale with treatment duration. In a cohort followed in the United Arab Emirates, participants treated for more than one year showed a median weight reduction of −22.6% versus −8.1% for those treated under one year, with corresponding long-term improvements in LDL-cholesterol (−30.5%), triglycerides (−32.5%), liver enzymes (SGOT −11.3%, SGPT −13.2%), and renal parameters including a 3.2% increase in estimated glomerular filtration rate. These findings reinforce tirzepatide's dual-receptor mechanism as producing effects that compound with sustained use, a pattern researchers are now investigating for mazdutide and retatrutide as longer follow-up data accumulates.

Side-by-side comparison

Differential research applications

Researchers select between the glucagon-receptor and GIP-receptor dual-agonist classes based on the metabolic outcome under study. Mazdutide's glucagon-receptor component makes it a candidate of interest in research examining hepatic fat content and thermogenic energy expenditure specifically, given the disproportionate liver-fat reduction observed in GLORY-1 relative to the degree of weight loss. Tirzepatide's GIP-receptor component, by contrast, is more frequently studied in the context of insulin sensitization and the cardio-metabolic-kidney continuum, where persistence-dependent renal and lipid benefits have been documented in real-world cohorts.

This mechanistic split also shapes how the two compounds are positioned relative to other agents in active development. Mazdutide sits alongside survodutide, another GLP-1/glucagon dual agonist, in a research track distinct from the GIP-based approach shared by tirzepatide and newer investigational agents. Researchers designing comparative protocols often group compounds by second-receptor target first, since glucagon-receptor and GIP-receptor agonism produce measurably different effects on hepatic and adipose tissue even when weight-loss magnitude is similar between arms. Tolerability profiles are broadly comparable across both mechanisms: gastrointestinal adverse events — nausea, diarrhea, and vomiting — are the most commonly reported findings in both mazdutide and tirzepatide trial populations, predominantly mild-to-moderate and transient, which researchers typically attribute to the shared GLP-1 receptor component rather than the differentiating second target.

Because both compounds are in active head-to-head and longitudinal study designs, researchers tracking new registrations and results can use the clinical trial tracker to monitor DREAMS-3 and related tirzepatide and mazdutide trial arms as they report. For researchers comparing molecular parameters directly, the molecular weight reference tool provides a side-by-side lookup across the incretin-agonist class, including semaglutide and other comparators. The evidence explorer is also useful for cross-referencing published study counts and evidence stage across the broader dual- and tri-agonist category.

Regulatory and compounding status

Tirzepatide holds FDA approval for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound), placing it outside the 503A/503B compounding bulk drug substance framework as an approved product available through standard pharmaceutical channels. Mazdutide's regulatory position is different: it has NMPA approval in China but remains investigational in the United States and most other jurisdictions, with its US compounding-eligibility status currently under review as part of the broader evaluation of newer incretin agonists entering the research and compounding pipeline. Researchers working across jurisdictions should treat mazdutide's regulatory status as a moving target pending outcomes of its ongoing global development program with Eli Lilly.

This asymmetry matters for how each compound is sourced in research settings. Tirzepatide's FDA-approved status means US-based researchers studying it in comparative or translational protocols typically work with the approved pharmaceutical product rather than a compounded or research-grade substance. Mazdutide, lacking US approval, is currently accessible to researchers primarily through its published trial data and, where applicable, jurisdictions where NMPA approval or separate research-chemical frameworks apply. This distinction is a common source of confusion in comparative literature searches, since Chinese-language regulatory filings and English-language trial publications sometimes lag each other by months, and researchers should confirm current status directly against primary regulatory sources rather than secondary summaries before designing any protocol that depends on compound availability.

Cited studies

• PMID 38092790 — "A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity." (2023). DOI: https://doi.org/10.1038/s41467-023-44067-4
• PMID 42029986 — "Persistence-Dependent Effectiveness of Tirzepatide on the Cardio-Metabolic-Kidney Syndrome Outcomes in Obesity: Real-World Evidence from the United Arab Emirates." (2026). DOI: https://doi.org/10.1056/NEJMoa2107519

Frequently asked questions

Q: What is the main mechanistic difference between mazdutide and tirzepatide?

A: Mazdutide pairs GLP-1 receptor agonism with glucagon receptor (GCGR) activation, while tirzepatide pairs GLP-1 receptor agonism with GIP receptor (GIPR) activation. Both are dual-receptor incretin agonists, but the second receptor target drives different downstream metabolic effects — glucagon signaling emphasizes hepatic and thermogenic pathways, while GIP signaling emphasizes insulin sensitization.

Q: Is mazdutide approved by the FDA?

A: No. Mazdutide has approval from China's National Medical Products Administration for type 2 diabetes and obesity management but remains investigational in the United States. Tirzepatide, by comparison, holds FDA approval for both indications.

Q: Which compound shows greater liver fat reduction in published trials?

A: Phase 3 GLORY-1 data for mazdutide reported liver fat content reductions of up to 80.2%, a magnitude researchers attribute to its added glucagon-receptor agonism. Tirzepatide's real-world cohort data also shows hepatic enzyme improvements, but the published effect size is smaller in the available comparative literature.

Q: Are mazdutide and tirzepatide being studied head-to-head?

A: Not directly against each other in a completed trial as of this writing. Mazdutide's Phase 3 DREAMS-3 trial compares it against semaglutide rather than tirzepatide. Indirect comparisons rely on separate trial populations and endpoints, which researchers should account for when interpreting relative efficacy.

Q: What does the "GCGR" abbreviation in mazdutide's mechanism refer to?

A: GCGR stands for glucagon receptor. Mazdutide's dual agonism activates both the GLP-1 receptor and GCGR, with the glucagon-receptor component contributing to increased energy expenditure and hepatic fatty acid oxidation alongside the appetite and glycemic effects mediated through GLP-1R.

See also:

• Retatrutide vs Tirzepatide: Triple vs Dual Agonist Mechanism Comparison — compares tirzepatide against a triple-receptor agonist for researchers evaluating the broader dual- vs tri-agonist landscape.
• Survodutide vs Tirzepatide: GLP-1/Glucagon vs GLP-1/GIP Dual Agonism in MASH and Obesity Research — a second GLP-1/glucagon dual agonist compared against tirzepatide, useful context for mazdutide's mechanistic class.
• Tirzepatide Mechanism of Action: Dual GIP/GLP-1 Agonism in Research — a deeper standalone look at tirzepatide's receptor pharmacology referenced throughout this comparison.

For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.